To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Allogeneic hematopoietic stem cell transplantation (HSCT) is essential for the long-term survival of acute leukemia (AL) patients. Peripheral blood stem cell transplantation has become the preferred method due to its lower invasiveness and convenience. The blood cell separator is key for hematopoietic progenitor cell collection, with CD34+ cell collection efficiency (CE) influencing transplant outcomes and healthcare costs. This study compares the cost-effectiveness of two devices, Spectra Optia and COM.TEC apheresis system, to assess their impact on CD34+ cell CE in HSCT.
Methods
A decision tree–Markov model was constructed from the perspective of the healthcare system to simulate the 5-year outcomes of 10,000 acute leukemia patients experiencing allogeneic stem cell transplantation. Resource cost differences between two devices were analyzed under two scenarios: minimizing resource consumption (scenario 1) and maximizing CD34+ cell volume (scenario 2). Cost-effectiveness analysis was undertaken combining quality-adjusted life years (QALYs) and total medical costs, with incremental net monetary benefit calculated at predefined willingness-to-pay thresholds.
Results
Compared to COM.TEC, Spectra Optia reduced apheresis times by 1–6 percent and improved the rate of engraftment success by 0.23 percent to 1.82 percent. In scenario 1, the net benefit per patient ranged from $634.85 to $1,260.43, and in scenario 2, the net benefit per patient ranged from $169.62 to $256.65.
Conclusion
Higher CE of the apheresis system optimizes both healthcare resource consumption and clinical outcomes. In the analysis considering the device price, Spectra Optia achieved cost-effectiveness dominance over COM.TEC at a surgical volume exceeding 121 cases per device.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.